These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2658728)

  • 1. Strategy for purification of coagulation factor concentrates.
    Clark DB; Drohan WN; Miekka SI; Katz AJ
    Ann Clin Lab Sci; 1989; 19(3):196-207. PubMed ID: 2658728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Present state and perspectives of the farctionation of human plasma, serum and placenta.
    Richter P
    Ann Immunol Hung; 1973; 17():85-92. PubMed ID: 4142679
    [No Abstract]   [Full Text] [Related]  

  • 3. Approaches to plasma fractionation for improved recovery and the development of potentially useful clinical factors.
    Johnson AJ; Mathews RW; Fulton AJ
    Clin Haematol; 1984 Feb; 13(1):3-15. PubMed ID: 6426834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biotechnology and the plasma fractionation industry--the impact of advances in the production of coagulation factor VIII.
    Farrugia A
    Australas Biotechnol; 1993; 3(1):16-20. PubMed ID: 7763537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral safety of coagulation factor concentrates.
    Mannucci PM
    Dev Biol Stand; 1993; 81():253-9. PubMed ID: 8174811
    [No Abstract]   [Full Text] [Related]  

  • 6. [Intracranial hemorrhage and hemostasis. Monitoring patients after intracranial hemorrhage by determination and follow-up of activation products of blood coagulation].
    Menges T; von Lessen A; Welters I; Wagner RM; Ruwoldt R; Boldt J; Hempelmann G
    Infusionsther Transfusionsmed; 1994 Aug; 21(4):244-50. PubMed ID: 7950289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research and development commitments in an integrated plasma collection and plasma fractionation environment.
    Radosevich M
    Semin Thromb Hemost; 1998; 24(2):157-61. PubMed ID: 9579637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Modern methods for the manufacture of therapeutic coagulation factors].
    Fuhge P; Gratz P; Geiger H
    Behring Inst Mitt; 1986 Feb; (79):165-76. PubMed ID: 3087341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New trends in plasma fractionation and plasma products.
    Burnouf T
    Vox Sang; 1994; 67 Suppl 3():251-3. PubMed ID: 7975504
    [No Abstract]   [Full Text] [Related]  

  • 10. [Plasma fractionation. Progress, problems and perspectives].
    Burnouf T
    Ann Pharm Fr; 1994; 52(3):124-36. PubMed ID: 7998759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma fractionation with special reference to the treatment of coagulation disorders.
    Bidwell E
    Proc R Soc Med; 1968 Jun; 61(6):598-600. PubMed ID: 5662213
    [No Abstract]   [Full Text] [Related]  

  • 12. Viral inactivation vs biological activity.
    Barrowcliffe TW
    Dev Biol Stand; 1993; 81():125-35. PubMed ID: 8174795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat treated New Zealand factor IX concentrate: comparison with Prothrombinex in patients with haemophilia B.
    Benny AG; Ockelford PA; Johns AS; Woodfield DG; Berry EW
    N Z Med J; 1986 Jun; 99(803):408-9. PubMed ID: 3461352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality control in the development of coagulation factor concentrates.
    Snape TJ
    Dev Biol Stand; 1987; 67():141-7. PubMed ID: 3609474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
    Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Product delivery in the developing world: options, opportunities and threats.
    Farrugia A
    Haemophilia; 2004 Oct; 10 Suppl 4():77-82. PubMed ID: 15479376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of large scale fractionation methods. VII. Preparation of antithrombin III concentrate.
    Wickerhauser M; Williams C; Mercer J
    Vox Sang; 1979; 36(5):281-93. PubMed ID: 462917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in factor VIII complex activities during the production of a clinical intermediate purity factor VIII concentrate.
    Prowse CV; Griffin B; Pepper DS; Dickson AJ; McQuillan TA; Dickson IH; Foster PR
    Thromb Haemost; 1981 Oct; 46(3):597-601. PubMed ID: 6797090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purification and properties of the thrombin-like principle of Agkistrodon acutus venom and its comparison with bovine thrombin.
    Ouyang C; Hong JS; Teng CM
    Thromb Diath Haemorrh; 1971 Oct; 26(2):224-34. PubMed ID: 5167421
    [No Abstract]   [Full Text] [Related]  

  • 20. Biochemical comparison of seven commercially available prothrombin complex concentrates.
    Kalina U; Bickhard H; Schulte S
    Int J Clin Pract; 2008 Oct; 62(10):1614-22. PubMed ID: 18691229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.